ReviewFrontiers in immunology2018
More than Decoration: Roles for Natural Killer Group 2 Member D Ligand Expression by Immune Cells.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- NKG2D ligand expression on NK cells induces NKG2D-mediated cross-tolerization of cytokine signaling and reduces NK cell tumor immunity.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- T cells with split CARs specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo.Journal of cancer research and clinical oncology · 2023Article
- Review
- Overcoming tumor resistance mechanisms in CAR-NK cell therapy.Frontiers in immunology · 2022Review
- Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects.Frontiers in immunology · 2022Review
- Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy.Frontiers in immunology · 2021Review
- Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.Oncoimmunology · 2020Article
- Effects of obesity on NK cells in a mouse model of postmenopausal breast cancer.Scientific reports · 2020Article
- NKG2D Signaling Within the Pancreatic Islets Reduces NOD Diabetes and Increases Protective Central Memory CD8Diabetes · 2020Article
- Lipoteichoic Acid Is Involved in the Ability of the Immunobiotic StrainFrontiers in immunology · 2020Article
- MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.Frontiers in immunology · 2020Article
- Constitutive expression of ULBP-4 on monocytes regulates NK cell NKG2D expression.Blood advances · 2019Article
- Human natural killer cells mediate adaptive immunity to viral antigens.Science immunology · 2019Article
- Enhancing Natural Killer and CD8Monoclonal antibodies in immunodiagnosis and immunotherapy · 2019Review
- Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges.Precision clinical medicine · 2019Review
- Genes controlling the activation of natural killer lymphocytes are epigenetically remodeled in intestinal cells from germ-free mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaFrontiers in immunology · 2019Article
- Impairment of NKG2D-Mediated Tumor Immunity by TGF-β.Frontiers in immunology · 2019Review
- CXCR6Frontiers in immunology · 2019Article
- The Paradoxical Role of NKG2D in Cancer Immunity.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The activating immune receptor natural killer group 2 member D (NKG2D), which is expressed by natural killer cells and T cell subsets, recognizes a number of ligands expressed by "stressed" or damaged cells. NKG2D has been extensively studied for its role in tumor immunosurveillance and antiviral immunity. To date, the majority of studies have focused on NKG2D-mediated killing of target cells expressing NKG2D ligands. However, with a number of reports describing expression of NKG2D ligands by cells that are not generally considered stressed, it is becoming clear that some healthy cells also express NKG2D ligands. Expression of these ligands by cells within the skin, intestinal epithelium, and the immune system suggests other immune functions for NKG2D ligand expression in addition to its canonical role as a "kill me" signal. How NKG2D ligands function in this capacity is just now starting to be unraveled. In this review, we examine the expression of NKG2D ligands by immune cells and discuss current literature describing the effects of this expression on immunity and immune regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.